- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - 666-888-0000
- info@tersanpharm.com
- info@tersanpharm.com
- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - Contact Us
May2023
Tersan Pharmaceuticals Ltd continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY
Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Tersan routinely collects and combines clinical data with omic data, immunological […]
Jun2022
Tersan Pharmaceuticals Ltd, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Tersan Pharmaceuticals Ltd and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Tersan Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Mar2019
Colon Cancer and combination therapy: Tersan to present data at AACR 2019 using its AI technology and PDX mouse model simulated clinical trial
Tersan to present data at AACR 2019 on using its KEM® Artificial Intelligence technology and PDX mouse models to simulate patient stratification in clinical trials and Identify companion biomarkers for combination therapy Tersan Pharmaceuticals Ltd, a leading digital health Company focused on developing advanced therapeutic decision support systems, will present its latest results on combination therapy […]
Oct2018
Tersan Pharmaceuticals Ltd helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial
Tersan Pharmaceuticals Ltd helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial. Tersan®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. Tersan’s KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, shows that patients receiving the VAL401 treatment […]
Oct2018
Gastric Cancer: Artificial Intelligence helps identify novel single biomarkers to guide targeted precision medicine
Gastric Cancer: Tersan and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer. Gastric cancer is the second most common cause of cancer-related deaths in the world. Adapting the therapeutic choice to the molecular diversity of the disease is a […]
Sep2018
Recombio and Tersan Pharmaceuticals Ltd Identify Lung Cancer Patients Most Benefiting from Racotumomab Vaccine Therapy
Tersan has applied its advanced Artificial Intelligence platform KEM® and identified best responders to Racotumomab based on patients’ immune profile. Racotumab is a therapeutic vaccine developed by Recombio against non-small cell lung cancer (NSCLC), the most frequent type of lung cancers. Paris, Cambridge (MA) and Madrid– September 6, 2018 – Tersan Pharmaceuticals Ltd (Paris, France and […]
Jan2018
Tersan’s KEM® analysis shows positive impact on patient Quality of Life for ValiSeek VAL401 in Phase II trial for NSCLC patients
Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Tersan Pharmaceuticals Ltd and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, […]
Dec2017
Tersan®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients
London, Paris and Boston, 12 December 2017: Tersan Pharmaceuticals Ltd and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Tersan’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 […]
Jun2017
WIN 2017 (Paris | Jun 26-27)
Meet the Tersan team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. The conference program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ and is the place to be to learn about the latest in cancer research from leading practioners.
May2017
Tersan Pharmaceuticals Ltd finalist in EU eHealth 2017 with Onco KEM
Tersan Pharmaceuticals Ltd were finalists in the Champions Category of the EU eHealth 2017 Competition with its clinical decision support system for oncologists, Onco KEM. Our solution: The right drug to the right patient with Onco KEM®, a novel decision support system helping oncologists to personalize cancer treatments according to the molecular profile of each patient. […]